Evidence map›Paper›PMID 42226151›Full record

ArticleBMC veterinary research2026

CRISPR-Cas9-mediated construction of a Streptococcus agalactiae vaccine for tilapia and evaluation of its protective efficacy.

Mianlong Huang, Xiufang Li, Taian Pan, Donghai Wu, Gonghe Li, Wende Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mianlong HuangCollege of Animal Science and Technology, Guangxi University, Nanning, 530004, China.
Xiufang LiGuangxi Vocational University of Agriculture, Nanning, 530007, China.
Taian PanCollege of Animal Science and Technology, Guangxi University, Nanning, 530004, China.
Donghai WuCollege of Animal Science and Technology, Guangxi University, Nanning, 530004, China.
Gonghe LiCollege of Animal Science and Technology, Guangxi University, Nanning, 530004, China.
Wende WuCollege of Animal Science and Technology, Guangxi University, Nanning, 530004, China. wwd0194@163.com.

Funding

Guangxi Science and Technology Program AA17204081-1the Fangchenggang Science and Technology Program AB22013007
6 · The paper itself

Abstract

backgroundStreptococcus agalactiae (GBS) causes severe tilapia streptococcosis with heavy aquaculture losses; existing vaccines have administration or efficacy limitations. This study used CRISPR-Cas9 to construct recombinant Escherichia coli DH5α-ORF4-GFP (targeting GBS scpB gene ORF4 fragment), optimized tilapia immersion immunization doses/frequencies, and evaluated the vaccine's protective efficacy, biosafety and regulatory effects via multi-dimensional assays.

resultsThe optimal regimen was single immersion at 1.5 × 10

conclusionsIn conclusion, this study successfully developed an effective and safe genetically engineered vaccine against GBS in tilapia. The precise CRISPR-Cas9-mediated construction strategy and confirmed immune protective effect provide a novel technical approach for controlling this disease in aquaculture and offer important references for the development of related genetically engineered vaccines.

Indexed as

CRISPR-Cas SystemsFish DiseasesStreptococcal InfectionsStreptococcal VaccinesStreptococcus agalactiaeTilapiaAnimalsStreptococcal VaccinesCRISPR-Cas9Immune protectionStreptococcus agalactiaeTilapiaVaccine

Identifiers

PMID42226151
PMCPMC13440110

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.